

Publicaties mevrouw dr. M.E.A. de Jager

1. Systemic treatments in paediatric psoriasis: a systematic evidence-based update. van Geel MJ, Mul K, de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM. *J Eur Acad Dermatol Venereol*. 2015 Mar;29(3):425-37. doi: 10.1111/jdv.12749. Epub 2014 Oct 23. Review.
2. The influence of treatments in daily clinical practice on the Children's Dermatology Life Quality Index in juvenile psoriasis: a longitudinal study from the Child-CAPTURE patient registry. Oostveen AM, de Jager ME, van de Kerkhof PC, Donders AR, de Jong EM, Seyger MM. *Br J Dermatol*. 2012 Jul;167(1):145-9. doi: 10.1111/j.1365-2133.2012.10996.x. Epub 2012 May 23.
3. Paediatric-onset psoriasis is associated with ERAP1 and IL23R loci, LCE3C_LCE3B deletion and HLA-C*06. Bergboer JG, Oostveen AM, de Jager ME, den Heijer M, Joosten I, van de Kerkhof PC, Zeeuwen PL, de Jong EM, Schalkwijk J, Seyger MM. *Br J Dermatol*. 2012 Oct;167(4):922-5. doi: 10.1111/j.1365-2133.2012.10992.x.
4. Koebner phenomenon in psoriasis is not associated with deletion of late cornified envelope genes LCE3B and LCE3C. Bergboer JG, Oostveen AM, de Jager ME, Zeeuwen PL, Joosten I, Seyger MM, Schalkwijk J. *J Invest Dermatol*. 2012 Feb;132(2):475-6. doi: 10.1038/jid.2011.336. Epub 2011 Nov 3. No abstract available.
5. The burden of childhood psoriasis. de Jager ME, De Jong EM, Evers AW, Van De Kerkhof PC, Seyger MM. *Pediatr Dermatol*. 2011 Nov-Dec;28(6):736-7. doi: 10.1111/j.1525-1470.2011.01489.x. Epub 2011 Jun 22.
6. Juvenile psoriasis in European and Asian children: similarities and differences. Chiam LY, de Jager ME, Giam YC, de Jong EM, van de Kerkhof PC, Seyger MM. *Br J Dermatol*. 2011 May;164(5):1101-3. doi: 10.1111/j.1365-2133.2010.10196.x. Epub 2011 Mar 21.
7. An inpatient comparison of quality of life in psoriasis in childhood and adulthood. de Jager ME, de Jong EM, van de Kerkhof PC, Evers AW, Seyger MM. *J Eur Acad Dermatol Venereol*. 2011 Jul;25(7):828-31. doi: 10.1111/j.1468-3083.2010.03872.x. Epub 2010 Oct 6.
8. A cross-sectional study using the Children's Dermatology Life Quality Index (CDLQI) in childhood psoriasis: negative effect on quality of life and moderate correlation of CDLQI with severity scores. de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM. *Br J Dermatol*. 2010 Nov;163(5):1099-101. doi: 10.1111/j.1365-2133.2010.09993.x.
9. Dithranol therapy in childhood psoriasis: unjustifiably on the verge of falling into oblivion. de Jager ME, van de Kerkhof PC, de Jong EM, Seyger MM. *Dermatology*. 2010;220(4):329-32. doi: 10.1159/000278241. Epub 2010 Apr 9.
10. No evidence found that childhood onset of psoriasis influences disease severity, future body mass index or type of treatments used. de Jager ME, de Jong EM, Meeuwis KA, van de Kerkhof PC, Seyger MM. *J Eur Acad Dermatol Venereol*. 2010 Nov;24(11):1333-9. doi: 10.1111/j.1468-3083.2010.03645.x.
11. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. de Jager ME, de Jong EM, van de Kerkhof PC, Seyger MM. *J Am Acad Dermatol*. 2010 Jun;62(6):1013-30. doi: 10.1016/j.jaad.2009.06.048. Epub 2009 Nov 8. Review.
12. Epidemiology and prescribed treatments in childhood psoriasis: a survey among medical professionals. de Jager ME, Van de Kerkhof PC, De Jong EM, Seyger MM. *J Dermatolog Treat*. 2009;20(5):254-8. doi: 10.1080/09546630902911847.